Navigation Links
New MedPredict Report Assesses Current Outlook for Anticoagulants Market
Date:2/20/2009

Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel

SCOTTSDALE, Ariz., Feb. 20 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology (ASH) annual meeting.

"Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis/pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation, and oncology," says Jeff Berk, MedPredict president. "Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals."

The report addresses the following questions:

  • Which patient populations are most likely to be prescribed Effient (prasugrel), and how are physicians likely to balance efficacy versus bleeding risk? How does this vary by specialty?
  • Is daily oral anticoagulant therapy preferable to a monthly parenteral dose?
  • What do acute coronary syndrome treaters want that pharma is not currently providing?
  • How do different specialists view the strengths and weaknesses of the various anticoagulant therapies in development?

"Our panel reviews all of the key compounds in the pipeline and distills a massive amount of information down to the most critical insights drug developers should have for decision-making," according to Dr. Berk.

Companies mentioned in
'/>"/>

SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Stout Industries ... firefighter with El Paso and Austin, Texas fire departments. Stout ... . There are three main components to these fire safety ... remain constant when the power is turned on. They light ... to clearly see what is on the roof, preventing leg ...
(Date:5/6/2015)... May 06, 2015 When it comes ... considered more reputable and respected than those of a ... by their physician lose more weight than those who ... conducted by the University of Georgia and published ... recently revealed that patients advised by their physicians dropped ...
(Date:5/6/2015)... Viejo, CA (PRWEB) May 06, 2015 ... unique and fun self-animating generators for Final Cut ... to add stylistic titles to a Final Cut Pro ... environments, adding professional quality openers to any shot has ... any skill level in mind, saving users time while ...
(Date:5/6/2015)... 2015 Spiking drug prices are taking large ... survey by The Senior Citizens League (TSCL). ... co-pays and co-insurance costs than expected in 2014 according to ... cost spikes may be tough for many beneficiaries to figure ... prices are commonly associated with brand and newer specialty drugs, ...
(Date:5/6/2015)... Chinese technology company, Elink-IOT, has launched a campaign ... to finalize development of Watcher, the world’s first anti-loss ... to help the owner keep track of important items ... is out of range. , Using a special ... sends alerts on its E-paper display, and also features ...
Breaking Medicine News(10 mins):Health News:Kickstarter for FIRE Lights, the New Fire Safety Devices 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 3Health News:Pixel Film Studios announces the release of Protrailer Cartoon Volume 2 for Final Cut Pro X. 2Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 2Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 3Health News:Crowdfunding campaign Launched for World’s First Anti-Loss Smart Watch 2
... zero in (on) the modalities of a drug, capable of ... trials on animal models have revealed the capacity of the ... charge of energy production., ,'Many drugs block the ... who is the Werner E. Bachmann Collegiate Professor of Chemistry ...
... renowned medical specialist, NHS can be freed from its’ ... reconsidered before they are implemented. // It is amply ... may make matters worse for the deprived and under ... has led to low morale among Doctors and NHS ...
... has announced the launch of BARACLUDE? (entecavir) for ... its approval by the Drug Controller General of India. ... of chronic hepatitis B virus infection in adults with ... persistent elevations in serum aminotransferases (ALT or AST) or ...
... warned that hospitals are repeatedly failing to implement rules ... to patients //from contaminated surgical instruments. ,The ... in sets so they can be traced easily. Instead ... ,Dr Gill Morgan, chief executive of the NHS ...
... with medical services functioning smoothly and the institute's director ... and attending to patients - a day after the ... ,While health services normalised in AIIMS after doctors, ... their agitation last evening following the court order, the ...
... diseases that has affected everyone from Henry VIII to Christoper ... near the site of infection//. The primary sore first appears ... clear. , This is followed by generalized skin rash, ... few months or years later tertiary syphilis develops which destroys ...
Cached Medicine News:Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/6/2015)... , May 6, 2015   Wilson Therapeutics ... CEO Jonas Hansson has been invited to ... the annual BioEquity Conference, this year to be held ... May 19 th . About WTX101 ... is currently in Phase 2 testing for Wilson Disease. ...
(Date:5/6/2015)... , May 6, 2015 ... join the Wellcome Trust and the Bill & ... Kymab, a leading monoclonal antibody biopharmaceutical ... an additional US$50 million to complete a US$90 ... being invested by Woodford Patient Capital Trust plc ...
Breaking Medicine Technology:ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Wilson Therapeutics To Present As A "Next Wave" Company During BioEquity 2015 Conference In Vienna On May 19th 2Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... March 31, 2012, on Thursday, May 10, 2012, following the ... an investor conference call and live webcast to discuss the ... Eastern Time / 2:00 p.m. Pacific Time on the same ...
... 2012 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI") ... today announced the signing of expanded strategic technology ... agreements, TDI now has the right to use ... Platform for their planned entry into the clinical ...
Cached Medicine Technology:Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 2Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 2Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 4Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 5Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 6
... The AlphaPette Pipettor is the ... beyond. Offers accuracy, comfort, and reliability. ... digital volume readout sub-micrometer. Easy interchangeable ... or tiny hands. Adjustable rapid pipet ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... Thermo Labsystems was designed specifically to combine ... such as the new fast dial system ... help to define this as a new ... interchangeable handle plate offers a custom fit ...
... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
Medicine Products: